OmiCure

OmiCure is writing the next chapter in human health and precision medicine in the fight against Cancer, taking our industry beyond big data and leading the way to a new category of products based on AI models. In this pursuit, we are using omics data to solve the most acute problems standing in the way of payers, physicians, and patients. Through our new generation of DNA, RNA microbiota-based tools, we will ensure the right patient is being provided with the right therapy at the right time. There are many personalized medicine companies that perform tumor profiling (such as DNA sequencing) of a patient’s tumor or blood, and generate a report that identifies tumor mutations and drugs that can be used to target individual mutations. OmiCure takes this to the next level: - We analyze the genetic sequencing performed on more than 22,000 genes while the other companies only analyze a panel of 70 to 500 genes. - Our Artificial Intelligence creates a score and ranks the top drug (out of more than 5 million options) that are customized for the patient. - We integrate multiple types of tumor profiling results (DNA/RNA sequencing, etc.) to get a more complete picture, when available. - We consider all of the latest advances in cancer care, including immunotherapy, targeted therapy, and newly approved cancer drugs, in addition to standard drug therapies. - We consider “off-label” cancer drugs in our analysis (i.e., drugs that have been approved for a different type of cancer, but that may be relevant to the patient’s specific tumor mutations based on data from prior clinical studies).